Article Text
Abstract
Aim To investigate the immunotherapeutic effectiveness of adenoviral vector expressing mouse interleukin (IL)-28B (Ad-mIL-28B) against cervical cancer and its mechanism.
Method U14 cervical cancer cell–bearing mice were treated with Ad-mIL-28B. Meanwhile, whole cell vaccine was prepared by repeated freezing and thawing U14 cells. Then CD4+CD25+FoxP3+regulatory T (Treg) cells were evaluated by flow cytometry. Tumor volume and metastasis in BALB/c and C57BL/6j mice were detected.
Results Ad-mIL-28B treatment significantly decreased the number of CD4+CD25+FoxP3+Treg cells. Subsequently, there was a significant decrease in the size of tumor tissue and the numbers of heteromorphic tumor cells. The tumor metastasis in the lung and liver of the Ad-mIL-28B group also decreased. However, there was no therapeutic effect observed for whole cell vaccine on U14 tumor–bearing mice.
Conclusion Interleukin-28B can inhibit the growth and metastasis of cervical cancer in U14 tumor–bearing mice by down-regulating Treg cells.
- IL-28B
- Cervical cancer
- Regulatory T cells
- Immunotherapy
- U14 cell
Statistics from Altmetric.com
Footnotes
This work were supported by the National Natural Science Foundation of China (81072499; http://www.nsfc.gov.cn/Portal0/default152.htm) and the Gansu Province Science and Technology Project of China (1105TCYA016; http://www.gsstc.gov.cn/).
The authors declare no conflicts of interest.